ERBB3 and non-small cell lung carcinoma: Thus, the antitumor activity of HER3-DXd alone or combined with osimertinib in NSCLC with progression on EGFR-TKIs treatment is being assessed in the clinical trials HERTHENA-Lung02 and NCT04676477, respectively.